Recent studies indicated that PPAR-γ agonist decreased expressions of inflammatory markers such as PAI-1, ICAM-1, and NF-κB in the kidney in DN and ameliorated renal function [93]. The gene discussed is NFKB1; the disease is liver dysplastic nodule.